News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 [Yahoo! Finance]

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]

Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.

Evaxion Biotech A/S (NASDAQ: EVAX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.

Form 6-K Evaxion Biotech A/S For: Apr 24

Form 6-K Evaxion Biotech A/S For: Apr 17

Form 6-K Evaxion Biotech A/S For: Apr 02

Form 6-K Evaxion Biotech A/S For: Mar 29

Form 6-K Evaxion Biotech A/S For: Mar 27

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}